Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience


October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces a drug discovery collaboration with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to generate innovative medicines in the neuroscience area.

The parties will engage in research programs to discover and advance candidate compounds for clinical development. Axcelead DDP will lead research activities to generate high-quality candidate compounds by leveraging its integrated drug discovery platform, deep knowledge and extensive experience of drug discovery research. Acadia will leverage its deep expertise in central nervous system disorders to execute clinical development and potential commercialization of successful compounds. Axcelead DDP will receive upfront fees, research funding and development milestone fees.

“Our mission is to contribute to the discovery of innovative drugs as the best partner for people engaged in drug discovery, based on the technology and know-how we have accumulated through our research in the pharmaceutical industry and the vast amount of drug discovery data we have collected,” said Yoshinori Ikeura Ph.D., chief executive officer of Axcelead. “We are delighted to collaborate with Acadia to potentially expand their development pipeline with the goals of delivering therapeutic drugs to patients suffering from neuropsychiatric diseases.

Axcelead DDP is Japan’s first drug discovery solution provider established in July 2017 by taking over the drug discovery platform from Takeda Pharmaceutical. Screening, Medicinal chemistry, Pharmacology / Biology, DMPK, and Safety research functions are integrated into one center with a state-of-the-art research base and original compound library. This enables Axcelead to create drug candidates by utilizing the vast amount of past drug discovery research data. By leveraging these strengths, we provide solutions to various challenges faced in the process from exploratory research to clinical in drug discovery.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years Acadia has been working at the forefront of healthcare to bring vital solutions to people who need them most. Acadia developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia’s clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit Acadia at

Axcelead acknowledges advisory and consulting support by InfiniteBio CEO, Akiko Futamura Ph.D. for this collaboration (HQ: Sunnyvale, CA)